The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Takeaway. What happened. GT Biopharma's stock was trading at $0.1880 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Get the hottest stocks to trade every day before the market opens 100% free. Post-Market 0.14 (5.67%) What has happened in October? (Updated on May 21, 2021) Buy or Hold candidate since 2021-03-19 Gain 117.91% PDF The GT Biopharma, Inc. stock price gained 3.83% on the last trading day (Friday, 21st May 2021), rising from $13.83 to $14.36. GTBP | Complete GT Biopharma Inc. stock news by MarketWatch. GT Biopharma might not be on the level that Pain Therapeutics is on, but the company still deserves some credit, as a nearly 15% increase is still a great way to start the trading week. Nasdaq: GTBP. Get the hottest stocks to trade every day before the market opens 100% free. “CANCER” Cancer takes the lives of millions every year. View detailed GTBP description & address. Click here now. The Company also retired over $32 million in debt and consolidated capital structure to 28,637,000 shares issued and outstanding. The stock price GT Biopharma Inc (NASDAQ: GTBP) increased by over 150% pre-market. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. GT Biopharma, Inc. Common Stock, also called GT Biopharma, is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. At that level they are trading at 0.248% discount to the analyst consensus target price of 0.00. GT Biopharma Inc. (GTBP): The stock long term indicators say Buy today. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. "CANCER" Cancer takes the lives of millions every year. Not only that but some of our readers may remember the company from last year before it uplisted to the NASDAQ. Sign $6,000,000.00 Agreement BEVERLY HILLS, CA / ACCESSWIRE / October 6, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform announced today that it had entered into a partnership agreement with Cytovance® Biologics, a USA-based contract development … to Chief Medical Officer and Jeffrey S. Miller, M.D. GTB-3550 Interim Results Presented at 62nd American Society of Hematology Annual Meeting and ExpositionBEVERLY HILLS, CA / ACCESSWIRE / December 8, 2020 / GT Biopharma, Inc. BEVERLY HILLS, CA / ACCESSWIRE / November 19, 2020 / GT Biopharma, Inc. The stock’s 5-day price performance is 16.56%, and it … The question becomes, what are the chances the stock … , and has now gained 3 days in a row. 10-Q Filing. Here’s what’s going on: Stop wasting your time! GT Biopharma, Inc is primarely in the business of pharmaceutical preparations. GT Biopharma has shown strength in the stock market this year. The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) – a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company’s proprietary NK cell engager (TriKE) protein biologic technology platform – has increased by … Of this total $230,000 was received as a salary, $0 was received as a bonus, $0 was received in stock options, $823,500 was awarded as stock and … Shares closed the week at $0.16 on October 18. The tender offer for all of the outstanding shares of Principia common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Friday, September 25, 2020. GT Biopharma a new buy at H.C. Wainwright The platform used by GT Biopharma (NASDAQ:GTBP) “constitutes a precision medicine assembly line” notes H.C. Wainwright analyst Robert Burns in initiating the coverage on the stock with a buy rating.The price target of … Find the latest news headlines from GT Biopharma, Inc. Common Stock (GTBP) at Nasdaq.com. ZIP XLS HTML. GT Biopharma Announces Closing of $23.7 Million Public Offering. GT Biopharma is way too risky over 90 days horizon: GT Biopharma appears to be risky and price may revert if volatility continues: GT Biopharma was previously known as GT Biopharma and was traded on NASDAQ Exchange under the symbol OXIS. Volume. Get the latest FULGENT GENETIC FLGT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The word we hate the most is the C word. : GT Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations BEVERLY HILLS, CA / ACCESSWIRE / March 10, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform announced today that it had entered into a collaboration agreement with Cytovance® Biologics, a USA-based contract development and … Moreover, as the company sets up for a major uplisting, the stock deserves your attention. View today's stock price, news and analysis for GT Biopharma Inc. (GTBP). We HATE cancer and we LOVE any company that has a mission to fight cancer. The stock spiked 0.97% in intraday trading to $14.50 this Friday, May 21, hitting a weekly high. We love GT Biopharma Ticker Symbol: GTBP GT Biopharma is a … According to Zacks, “GT Biopharma Inc. is an immuno-oncology company. Shares in GT Biopharma Inc are currently priced at $13.83. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT Biopharma, Inc. (NASDAQ:GTBP) traded at $10.44 at close of the session on Friday, Apr 09, made an upward move of 18.77% on its previous day’s price. GTBP: Get the latest GT Biopharma stock price and detailed information including GTBP news, historical charts and realtime prices. We HATEcancer and we LOVE any company that has a mission to fight cancer. In a press release issued this morning, GT Biopharma announced that it has entered into a collaboration agreement with Cytovance Biologics. stock was originally listed at a price of $28.22 in Mar 27, 2018. View FULGENT GENETIC FLGT investment & stock information. View the latest GT Biopharma Inc. (GTBP) stock price, news, historical charts, analyst ratings and financial information from WSJ. GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET From BusinessInsider May 18, 2021 GT Biopharma, Inc. (GTBP) registered a 3.83% upside in the last session and has traded in the green over the past 5 sessions. GT Biopharma Inc. is an immuno-oncology company. As of this writing, GT Biopharma is trading a $5.12, putting the stock up $0.62, or 13.78%. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida. Dow Jones futures rose 0.9% vs. fair value. Closed $28.7 Million Public Offering and Successful Nasdaq Listing: In February 2021, GT Biopharma announced the closing of an underwritten public offering extending GT Biopharma… GTBP, GT Biopharma Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines GT Biopharma. As of 1:24 p.m. EDT, 9 Meters Biopharma's stock was GT Biopharma Inc. [NASDAQ: GTBP] gained 28.85% on the last trading session, reaching $5.85 price per share at the time. View real-time stock prices and stock quotes for a full financial overview. Successful completion of NASDAQ uplist. Company profile for GT Biopharma Inc. including key executives, insider trading, ownership, revenue and average growth rates. Industry. The stock price GT Biopharma Inc (NASDAQ: GTBP) – a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE) for cancer – increased by over 150% pre-market as of 4:44 AM ET. * AS OF MARCH 31, 2021, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $27.6 MILLION, COMPARED TO $5.3 MILLION AS OF DECEMBER 31, 2020 Source text for Eikon: Further company coverage: GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. GT Biopharma, Inc quote is equal to 14.920 USD at 2021-05-06. Their average twelve-month price target is $23.00, predicting that the stock has a possible upside of 60.17%. Find the latest GT Biopharma, Inc. (GTBP) stock quote, history, news and other vital information to help you with your stock trading and investing. The Company’s stock begins trading under the new symbol today. The SEC Form 4 filings 9 Meters Biopharma released yesterday disclose that the company's CEO, John Temperato, bought 100,000 shares of the company's stock … Dow Jones Futures Today. Since then, GTBP shares have increased by 8,033.0% and is now trading at $15.29. Analysts covering GT Biopharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.47 for the next financial year. This report has 4 sections that will help you gain valuable insights regarding GT Biopharma Inc (GTBP) stock's past 10-year history. * Q1 LOSS PER SHARE $1.83. Find real-time GTBP - GT Biopharma Inc stock quotes, company profile, news and forecasts from CNN Business. GT Biopharma, Inc. Investor Day Presentation as of May 19, 2021. This is why it happened. 2 Wall Street analysts have issued ratings and price targets for GT Biopharma in the last 12 months. 52 week Low/High. S&P 500 futures climbed 1.1%. With a 5-year investment, the revenue is expected to be around +161.84%. So what’s happened with GT Biopharma this month? GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET May 18, 2021 • 9:50 EDT | Read More. HTML Financials. * AS OF MARCH 31, 2021, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $27.6 MILLION, COMPARED TO $5.3 MILLION AS OF DECEMBER 31, 2020 Source text for Eikon: Further company coverage: PDF HTML Release. Shares of 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage biotech company, are trading higher on Wednesday after the company filed documents with the U.S. Securities and Exchange Commission (SEC) indicating that several of its executives have recently purchased shares of the company. Price. GT Biopharma, Inc. Common Stock (GTBP) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. About GT Biopharma Inc.: GT Biopharma is a pharmaceutical company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. to Chief Medical Officer and Jeffrey S. Miller, M.D. GT Biopharma's stock was trading at $0.1880 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GTBP shares have increased by 2,357.4% and is now trading at $4.62. View which stocks have been most impacted by COVID-19. LOS ANGELES, CA / ACCESSWIRE / August 21, 2017 / GT Biopharma Inc. (formerly known as Oxis International, Inc.) announced today a 1-for-300 reverse stock split. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Shares in GT Biopharma Inc are currently priced at $7.19. LOS ANGELES, CA / ACCESSWIRE / September 5, 2017 / GT Biopharma Inc. announced today the closing of the merger of GT Biopharma, Inc. (formerly Oxis International Inc.) (OTCQB: OXISD) and Georgetown Translational Pharmaceuticals Inc. The word we hate the most is the C word. PDF HTML. GT Biopharma Inc. (NASDAQ: GTBP) is 33.60% higher on its value in year-to-date trading and has touched a low of $2.04 and a high of $13.09 in the current 52-week trading range. GT Biopharma reports Q1 results May 17, 2021 11:46 PM ET GT Biopharma, Inc. (GTBP) GT Biopharma, Inc. (GTBP) By: Jignesh Mehta , SA News Editor GT Biopharma (NASDAQ: GTBP ) : Q1 GAAP EPS of -$1.83. The average GT Biopharma stock price prediction forecasts a potential downside of N/A from the current GTBP share price of $14.36. A total of 16 insider transactions have happened at GT Biopharma Inc. (GTBP) in the last six months, with sales accounting for 16 and purchases happening 0 times. GT Biopharma's share price could stay at $23.00 by Apr 13, 2022. GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company can be reached via phone at 800-304-9888 or via email at info@oxis.com. GT Biopharma Inc (GTBP): * GT BIOPHARMA REPORTS FIRST QUARTER 2021 RESULTS. As Chief Financial Officer at GT BIOPHARMA INC, Steven Weldon made $1,053,500 in total compensation. In fact, not counting the 1-2 day rallies of 5-10%, since June 4 there has been a number of moves as … Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 5:02:33 PM Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/28/2021 6:08:25 AM GT Biopharma names Gregory Berk Chief Medical Officer Seeking Alpha - 4/26/2021 7:56:10 AM: GT Biopharma Announces the Appointments of Gregory Berk, M.D. PDL BioPharma, Inc. NASDAQ Updated May 11, 2021 4:00 AM PDLI 2.47 0.23 (8.52%). GT Biopharma currently has 2 buy ratings from Wall Street analysts. The high price target for GTBP is $25.00 and the low price target for GTBP is $21.00. The Company develops drugs focused on the treatment of cancer. Weaker technical forecast for GT Biopharma, Inc. as stock downgraded to Buy Candidate. GT Biopharma News: GTBP Stock Spikes 26% on Coronavirus Treatment Hopes GTBP is working with Cytovance Biologics for its treatment By William … XBRL. Analysts covering GT Biopharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.23 for the next financial year. A total of 16 insider transactions have happened at GT Biopharma Inc. (GTBP) in the last six months, with sales accounting for 16 and purchases happening 0 times. This is why it happened. The GTBP share’s 52-week high remains $13 BEVERLY HILLS, Calif.-- (BUSINESS WIRE)--GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed ... 3 months ago - Business Wire. Starting on October 4, GTBP stock has managed to jump from $0.125 to highs of $0.1995 last week. The stock has a consensus analyst rating of "Buy." GT Biopharma, Inc.’s stock price is currently approximately $ 15.24. to Consulting Chief Scientific Officer PR 04/20 Day Low/High. This small-cap biotech stock has been in an uptrend for most of the month. Your current $100 investment may be up to $261.84 in 2026. Stock Information. Zacks Investment Research lowered shares of GT Biopharma (OTCMKTS:GTBP) from a hold rating to a sell rating in a research note issued to investors on Tuesday, Zacks.com reports. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic … GT Biopharma’s lead treatment, GTB-1550 is a novel multi-target directed therapy for the treatment of chemotherapy-refractory B-cell malignancies, including Non-Hodgkins Lymphoma and Leukemia. Change. Nasdaq 100 futures advanced 1.45%. Cytovance is a United States-based contract development and manufacturing organization. Shares of Matinas BioPharma Holdings (NYSEMKT:MTNB) were crashing 32.7% lower as of 3:01 p.m. EST on Monday. BEVERLY HILLS, CA / ACCESSWIRE / March 10, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform announced today that it had entered into a collaboration agreement with Cytovance® Biologics, a USA-based contract development and … In a report issued on May 10, B.Riley Financial also reiterated a Buy rating on the stock with a $21.00 price target. At the close of trading, the stock’s price was $11.54, to imply an increase of 16.57% or $1.64 in intraday trading. View the latest ratings for GTBP. Mar 31, 2021. The number of shares of GT Biopharma restricted common stock was based on the closing price ($0.31) of the Company's common stock on December 15, 2020. Reddit Penny Stocks To Watch #1: GT Biopharma Inc. (NASDAQ: GTBP) Biotech penny stocks were hot earlier this year, cooled off at the end of Q1, and have recently heated back up in May. Get the hottest stocks to trade every day before the market opens 100% free. The Company develops drugs focused on the treatment of cancer. The data range used to generate this report is between 2011-04-26 and 2021-04-23. GT BIOPHARMA : Announces the Appointments of Gregory Berk, M.D. For financial reporting, their fiscal year ends on December 31st. Find the latest news headlines from GT Biopharma, Inc. Common Stock (GTBP) at Nasdaq.com. If you had invested in GT Biopharma stock at $28.22, your return over the last 3 years would have been -45.82%, for an annualized return of -18.48%. Shares of Matinas BioPharma Holdings (NYSEMKT:MTNB) were crashing 32.7% lower as of 3:01 p.m. EST on Monday. GT Biopharma Reports First Quarter 2021 Results May 17, 2021 • 6:54 EDT | Read More Granted that it has been a quiet and steady move, all the same, this penny stock has turned heads in October. The company report on March 8, 2021 that GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer.. Get the hottest stocks to trade every day before the market opens 100% free. The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) has increased by over 3% pre-market. Furthermore, this quarter has shown a clear, bullish trend in related sector ETFs like the XLV. The merger brings GT Biopharma, Inc a new Chief Executive Officer, a robust intellectual property portfolio, and a multi-million dollar financing that leaves the Company well-positioned to continue pursuing its pipeline of oncology and Central Nervous System … MKT Cap. The company announced that it has completed a private offering, even in the midst of the COVID-19 pandemic. At that level they are trading at 75.44% discount to the analyst consensus target price of 0.00. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and … GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET. By Heidi Phillips May 19, 2021 How have the shares performed? GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. It will be exciting to see whether it manages to … If you had invested in GT Biopharma stock at $28.22, your return over the last 3 years would have been -45.82%, for an annualized return of -18.48%.
Aks Design Considerations, Climate Change Adaptation Funding, Taylor Swift Woodvale Album, Quarterback Fake Handoff, Clean Energy Washington, Dc, Jumping Worms Australia, Effective Field Goal Percentage Leaders 2020-2021,